Regeneron Sets Out Timing Expectations For Dupixent Biosimilars
Originator Indicates Expected Market Formation Dates For Dupilumab Rivals To $12bn Brand
At the recent Morgan Stanley Healthcare Conference in New York, Regeneron management set out expectations for when the firm would begin to face competition to its $12bn-and-growing Dupixent eczema and asthma treatment from dupilumab biosimilars in the US, Europe and Japan.
